1 year ago
This webinar will discuss the clinical pharmacology considerations for the development of novel therapeutic modalities. Our FDA subject matter experts will also address the unique considerations for oligonucleotide therapeutics and antibody-drug conjugates with respect to topics such as dose selection, exposure/response analysis, organ impairment, drug interactions, QTc assessment, and immunogenicity.
Register here ➡️ Clinical Pharmacology Considerations for Novel Therapeutic Modalities - 12/04/2024 | FDA